去纤苷（去纤维钠）的用法用量

Defibrotide (defiteli sodium/defiteli) was first developed by Gentium Pharmaceuticals of Italy. It was approved for marketing in the European Union in October 2013, and was approved for marketing in the United States by the U.S. Food and Drug Administration (FDA) on March 30, 2016. Indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT).

Usage and dosage of defibrotide (sodium defibrination):

The recommended dose of defibrotide (Defibrotide Sodium) for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Defibrotide was administered for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrination until resolution of VOD or up to a maximum of 60 days. Defibrotide must be diluted prior to infusion.

Prior to administration of defibrotide, confirm that the patient is not experiencing clinically significant bleeding and is hemodynamically stable on no more than one vasopressor. Defibrotide was administered by constant intravenous infusion over a 2-hour period. Administer the diluted defibrotide solution using an infusion set equipped with a 0.2 μm in-line filter. Flush the intravenous administration line (peripheral or central) with 5% Dextrose Injection, USP, or 0.9% Sodium Chloride Injection, USP, before and immediately after administration. Do not coadminister defibrotide (desoside) with other intravenous medications at the same time and in the same intravenous line.

Concomitant use of defibrotide (defiteli) and a systemic anticoagulant or fibrinolytic therapy (excluding use for routine maintenance or central venous line reopening) may increase the risk of bleeding. Discontinue anticoagulants and fibrinolytics before defibrotide therapy, and consider delaying initiation of defibrotide administration until the effects of the anticoagulant have lessened.